|Budget Amount *help
¥16,120,000 (Direct Cost: ¥12,400,000、Indirect Cost: ¥3,720,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2015: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|Outline of Final Research Achievements
For development of a versatile human induced pluripotent stem cells (hiPSc) method, HiPSc induction was performed with patient’s primary somatic cells that are fibroblasts from the skin and the heart. However, induction efficacy of hiPSc was very low compared with that of commercial available human fibroblasts. The fibroblasts from the remainder tissue after surgery highly expressedα－SMA（smooth muscle actin）, so-called these are myofibroblats. Although using the myofibroblasts, it was very hard to create hiPSc, an initial medium without TGF-βfor hiPSc induction led to development of hiPSc successfully. But it was still low efficacy. Using the hiPSc from the myofibroblasts, we achieved the cardiomyocytes differentiation.